lopinavir/ritonavir in COVID-19 mild to moderate - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias deathsdetailed results Hung et al., 2020 (REV) 2.11 [0.04; 108.31]
Solaymani-Dodaran, 2021 (REV) 0.82 [0.44; 1.51]
0.84 [0.46 ; 1.54 ] Hung et al., 2020 (REV), Solaymani-Dodaran, 2021 (REV) 2 0% 500 moderate not evaluable clinical deteriorationdetailed results ELACOI (lopinavir/ritonavir), 2020 3.69 [0.37; 36.57]
3.69 [0.37 ; 36.57 ] ELACOI (lopinavir/ritonavir), 2020 1 0% 28 NA not evaluable clinical improvementdetailed results Hung et al., 2020 (REV) 0.26 [0.11; 0.60]
0.26 [0.11 ; 0.60 ] Hung et al., 2020 (REV) 1 0% 127 NA not evaluable clinical improvement (time to event analysis only)detailed results Hung et al., 2020 (REV) 0.26 [0.11; 0.60]
Solaymani-Dodaran, 2021 (REV) 1.06 [0.85; 1.33]
0.55 [0.14 ; 2.24 ] Hung et al., 2020 (REV), Solaymani-Dodaran, 2021 (REV) 2 90% 507 moderate not evaluable mechanical ventilationdetailed results Solaymani-Dodaran, 2021 (REV) 0.62 [0.32; 1.18]
0.62 [0.32 ; 1.18 ] Solaymani-Dodaran, 2021 (REV) 1 0% 373 NA not evaluable radiologic improvement (14-day)detailed results ELACOI (lopinavir/ritonavir), 2020 0.48 [0.02; 11.28]
0.48 [0.02 ; 11.28 ] ELACOI (lopinavir/ritonavir), 2020 1 0% 25 NA not evaluable radiologic improvement (7-day)detailed results ELACOI (lopinavir/ritonavir), 2020 0.10 [0.00; 2.09]
0.10 [0.00 ; 2.09 ] ELACOI (lopinavir/ritonavir), 2020 1 0% 25 NA not evaluable viral clearance detailed results ELACOI (lopinavir/ritonavir), 2020 1.28 [0.19; 8.76]
Hung et al., 2020 (REV) 0.23 [0.10; 0.54]
0.43 [0.08 ; 2.20 ] ELACOI (lopinavir/ritonavir), 2020, Hung et al., 2020 (REV) 2 61% 155 moderate not evaluable viral clearance (time to event analysis only)detailed results Hung et al., 2020 (REV) 0.23 [0.10; 0.54]
0.23 [0.10 ; 0.54 ] Hung et al., 2020 (REV) 1 0% 127 NA not evaluable viral clearance by day 14detailed results ELACOI (lopinavir/ritonavir), 2020 1.28 [0.19; 8.76]
ELACOI (Lopinavir/ritonavir), 2020 (REV) 0.54 [0.12; 2.48]
0.76 [0.23 ; 2.48 ] ELACOI (lopinavir/ritonavir), 2020, ELACOI (Lopinavir/ritonavir), 2020 (REV) 2 0% 97 moderate not evaluable viral clearance by day 7detailed results ELACOI (lopinavir/ritonavir), 2020 0.30 [0.05; 1.91]
ELACOI (Lopinavir/ritonavir), 2020 (REV) 0.92 [0.35; 2.47]
0.70 [0.27 ; 1.81 ] ELACOI (lopinavir/ritonavir), 2020, ELACOI (Lopinavir/ritonavir), 2020 (REV) 2 9% 97 moderate not evaluable ICU admissiondetailed results Solaymani-Dodaran, 2021 (REV) 0.81 [0.46; 1.44]
0.81 [0.46 ; 1.44 ] Solaymani-Dodaran, 2021 (REV) 1 0% 373 NA not evaluable severe COVID-19 occurrencedetailed results ELACOI (Lopinavir/ritonavir), 2020 (REV) 3.28 [0.79; 13.64]
3.28 [0.79 ; 13.64 ] ELACOI (Lopinavir/ritonavir), 2020 (REV) 1 0% 69 NA not evaluable serious adverse eventsdetailed results Hung et al., 2020 (REV) 4.28 [0.14; 130.10]
4.28 [0.14 ; 130.10 ] Hung et al., 2020 (REV) 1 0% 127 NA not evaluable 0.0 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-04-28 19:31 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
